10 Best Diabetes Stocks To Buy According to Billionaires

7. Novo Nordisk A/S (NYSE:NVO)

Number of Billionaires: 11

Dollar Value of Billionaire Holdings: $3,396,274,951

Novo Nordisk A/S (NYSE:NVO), standing seventh among the best diabetes stocks to buy according to billionaires, is a global healthcare leader specializing in diabetes care, obesity management, and chronic diseases, with diabetes treatments making up 85% of its business. Its portfolio includes insulin analogs, GLP-1 receptor agonists, and oral antidiabetic drugs like Rybelsus, Ozempic, and Tresiba.

Novo Nordisk A/S (NYSE:NVO) delivered exceptional financial results in 2024, which was driven by strong demand for its diabetes and obesity treatments. Their revenue surged 25% to DKK 290.4 billion ($40.5 billion), with Q4 revenue alone rising 30% year-over-year. This growth was primarily fueled by semaglutide-based drugs like Wegovy and Ozempic, which generated DKK 186 billion ($24.9 billion), accounting for 60% of total sales.

The company’s profitability remained strong, with operating profit increasing 26% to DKK 128.3 billion and net profit rising 21% to DKK 101 billion. Despite higher R&D expenses (+48%), gross margin improved to 84.7%, reflecting efficient cost management. Operating cash flow reached DKK 121 billion, though free cash flow turned negative due to capital expenditures and the Catalent acquisition.

Investors remain optimistic about Novo Nordisk A/S (NYSE:NVO) due to pipeline innovation with promising drugs like CagriSema and amycretin, supply chain improvements resolving Wegovy shortages, and strategic acquisitions, including Catalent sites, which enhance production capacity and ensure long-term supply stability.